Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). (Q38454062)
Jump to navigation
Jump to search
scientific article published on 23 March 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). |
scientific article published on 23 March 2013 |
Statements
1 reference
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). (English)
1 reference
Pieter Dewint
1 reference
Elke Verhey
1 reference
Bas Oldenburg
1 reference
Daniel W Hommes
1 reference
Marieke Pierik
1 reference
Cyriel I J Ponsioen
1 reference
Hendrik M van Dullemen
1 reference
Maurice Russel
1 reference
Ad A van Bodegraven
1 reference
C Janneke van der Woude
1 reference
23 March 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference